<DOC>
	<DOCNO>NCT01241383</DOCNO>
	<brief_summary>Systemic sclerosis ( SSc ) connective tissue disease characterize excessive collagen deposition , autoimmunity vascular hyper-reactivity obliterative microvascular phenomenon involve multiple organ . Scleroderma Renal Crisis ( SRC ) occur 5 % patient mainly diffuse cutaneous SSc . The routine use angiotensin-converting enzyme inhibitor ( ACEI ) report dramatically improve outcome , fall 12-month mortality 76 % le 15 % United-States . Despite prognostic improvement , SRC remain severe manifestation SSc functional outcome survival remain poor . Bosentan specific , orally active , dual endothelin receptor antagonist recently approve treatment primary pulmonary arterial hypertension prevention ischemic digital ulcer . Bosentan could therapeutic benefit others vascular injury particularly SRC .</brief_summary>
	<brief_title>Effect Bosentan Scleroderma Renal Crisis</brief_title>
	<detailed_description>Systemic sclerosis ( SSc ) connective tissue disease characterize excessive collagen deposition , autoimmunity vascular hyper-reactivity obliterative microvascular phenomenon involve multiple organ . Scleroderma Renal Crisis ( SRC ) occur 5 % patient mainly diffuse cutaneous SSc . The routine use angiotensin-converting enzyme inhibitor ( ACEI ) report dramatically improve outcome , fall 12-month mortality 76 % le 15 % United-States . Despite prognostic improvement , SRC remain severe manifestation SSc functional outcome survival remain poor . Bosentan specific , orally active , dual endothelin receptor antagonist recently approve treatment primary pulmonary arterial hypertension prevention ischemic digital ulcer . Bosentan could therapeutic benefit others vascular injury particularly SRC .</detailed_description>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>Men woman â‰¥ 18 year Patients fulfil ACR and/or LEROY et MEDSGER criteria systemic sclerosis Patients fulfil criterion renal systemic sclerosis Written inform consent obtain Scleroderma renal crisis occur age eighteen Patients receive bosentan within one month inclusion pulmonary arterial hypertension digital ulcer prevention Other treatment selective nonselective antagonist endothelin receptor Left ventricle systolic dysfunction ( EF &lt; 40 % ) Patients systolic blood pressure &lt; 85mm Hg Progressive cancer consider cure less 5 year Patients know hypersensitivity bosentan excipients Patients HIV , HCV , HBV infection Patients Liver disease ChildPugh B C Patients pregnant breastfeed Women childbearing age sexually active without practise reliable method contraception Patients give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Scleroderma renal crisis</keyword>
	<keyword>angiotensin convert enzyme inhibitor</keyword>
	<keyword>bosentan</keyword>
	<keyword>endothelin receptor antagonist</keyword>
</DOC>